



## **<sup>99m</sup>Tc-maraciclalide Abstracts To be Presented at SNMMI 2026**

**London, UK, 20 May 2026.** [Serac Healthcare Limited](#) (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that two abstracts on <sup>99m</sup>Tc-maraciclalide will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting taking place from 30 May to 2 June in Los Angeles, USA.

Dr Druin Burch, Scientific Director at Serac Healthcare will be giving an oral presentation on **“Imaging Lung Inflammation in Interstitial Lung Disease (ILD) with <sup>99m</sup>Tc-Maraciclalide – a Therapy Selection Tool?”** (abstract #1910)

**Session:** IS04 General Clinical Specialties Scientific Session

**Date:** Sunday, May 31, 2026

**Time:** 3:30 PM - 4:45 PM

**Location:** Convention centre, IS room

The abstract is available here:

<https://www.xcdsystem.com/snmml/program/UtDKfSi/index.cfm?pgid=3058&sid=53879&mobileap pid=5387900000>

Phase II preliminary data from the PROspective Evaluation of Interstitial Lung Disease progression with quantitative CT (PREDICT-ILD) trial have previously demonstrated that visualisation of inflammation in people with fibrotic-ILD could be feasible with <sup>99m</sup>Tc-maraciclalide.

A further abstract (#1985), **Semi-quantitative Analysis of Endometriosis Subtypes Using <sup>99m</sup>Tc-Maraciclalide SPECT-CT**, has been accepted for poster presentation and will be available to view in the Science Pavilion throughout the conference. Dr Burch will also be giving a short oral overview of the poster as part of the Meet the Author session:

**Session:** MTA01 General Clinical Specialties Meet the Author Session (#261985 MTA01-Screen 09)

**Date:** Sunday 31<sup>st</sup> May

**Time:** 1-1.45pm

**Location:** Science Pavilion

The abstract is available here:

<https://www.xcdsystem.com/snmml/program/UtDKfSi/index.cfm?pgid=3058&sid=53877&mobileap pid=5387700000>

Phase 2 data from the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” (DETECT) imaging study have indicated that <sup>99m</sup>Tc-maraciclalide has potential as a promising diagnostic and monitoring tool for endometriosis.

<sup>99m</sup>Tc-maraciclalide has FDA Fast Track designation both for “the visualisation of inflammation in the lungs of patients with known and suspected ILD” and for “the visualisation and diagnosis of superficial peritoneal endometriosis”.

**-ENDS-**

**<sup>99m</sup>Tc-maraciclalide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.**

**For more information, please contact:**

Serac Healthcare Ltd

[www.serachealthcare.com](http://www.serachealthcare.com)

David Hail, Chief Executive Officer

+44 (0)208 948 0000  
[info@seraclifesciences.com](mailto:info@seraclifesciences.com)

Francetta Carr, Communications Director

+44 (0)7711 010820  
[francettacarr@seraclifesciences.com](mailto:francettacarr@seraclifesciences.com)

**Notes to Editors**

**About Serac Healthcare Ltd**

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis, inflammatory arthritis and interstitial lung disease, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

**About <sup>99m</sup>Tc-maraciclptide**

<sup>99m</sup>Tc-maraciclptide is a radio-labelled tracer which binds with high affinity to  $\alpha v\beta 3$  integrin, a cell-adhesion molecule which is up-regulated in vascular endothelial cells during angiogenesis, a key biological process that occurs during inflammation.

**About SNMMI:** [www.snmmi.org/AM](http://www.snmmi.org/AM)